A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS1)

Conditions

Children's Health | Headaches

Phase III

Volunteers
Health Professionals

What is the purpose of this trial?

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.

Ages
6 years - 17 years
Gender
Both

Find out more about who can participate in this trial

Trial with
Eli Lilly and Company
Start Date
03/02/2021
End Date
08/30/2022

For more information about this study, contact:

Catherine Tsao

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Cristian Ionita, MD
Associate Professor of Clinical Pediatrics (Neurology); Director of the Pediatric Neurology Residency Program; Co-Director Yale/MDA Pediatric Neuromuscular Clinic

Last Updated
12/22/2022
Study HIC
#2000028680

A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS1)

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Contact Information